Skip to content
Open access

Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel–NK2R Interaction

Aug 2026 · Bioengineering · Vol 13, pp. 953 · 0 citations · 66 references
Medicine

TL;DR

The results support the structural feasibility of a previously uncharacterized receptor interaction and provide a reproducible computational framework for exploring GPCR-associated effects of cytotoxic agents.

Abstract

Background: Paclitaxel is a cornerstone chemotherapeutic agent widely used in breast cancer treatment, primarily through the stabilization of microtubule dynamics. Beyond its canonical tubulin-targeting activity, increasing evidence suggests that paclitaxel may engage additional molecular targets, contributing to its complex pharmacological profile. In this study, an integrated computational workflow was applied to evaluate the structural compatibility between paclitaxel and the neurokinin-2 receptor (NK2R), a G protein-coupled receptor involved in tumor-associated inflammatory and proliferative signaling pathways. Physicochemical profiling and target prediction were performed using SwissADME and SwissTargetPrediction, followed by molecular docking and molecular dynamics simulations using AutoDock Vina and GROMACS 2024.1. Paclitaxel exhibited physicochemical properties consistent with transient interactions in hydrophobic transmembrane environments. Docking analysis identified a plausible binding mode within the NK2R transmembrane cavity, primarily stabilized by hydrophobic contacts. Molecular dynamics simulations over 100 ns revealed stable ligand occupancy and overall complex stability, while MM-PBSA calculations indicated a favorable transient association. The predicted interaction is consistent with secondary or non-canonical receptor engagement. While NK2R is not established as a pharmacological target of paclitaxel, the results support the structural feasibility of a previously uncharacterized receptor interaction and provide a reproducible computational framework for exploring GPCR-associated effects of cytotoxic agents.

Read PDF

Similar papers

Sep 2026

Molecular simulation reveals spontaneous allosteric binding of BMS-357075 to human cyclin-dependent kinase 20.

Cyclin-dependent kinase 20 (CDK20) is a promising oncology target, but the lack of high-resolution complex structures limits drug development. Here, we investigated the spontaneous association of BMS-357075 with CDK20 using microsecond-scale unbiased molecular dynamics simulations, including an extended 2.0-μs trajecto...

Hai-Xia Zhu, Wen-Shuai Xuan, Yan-Hong Wang et al. · 0 citations
Open access Aug 2026

Structure-based discovery of novel ROCK2 inhibitors using integrated virtual screening, molecular dynamics, metadynamics and absolute binding free energy calculations

A structure-based computational strategy to identify and characterize novel ROCK2 inhibitors is presented, applicable to the discovery of both small-molecule and peptidomimetic inhibitors, supporting broader efforts in structure-guided drug design targeting kinases involved in cancer and other diseases.

Shradheya R. R. Gupta, R. Rameshwari, Indrakant K. Singh et al. · 0 citations
Oct 2026

Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds.

Structural, conformational, energetic, and pharmacokinetic characterization of dutasteride, danazol, and azelastine as candidate CDK6-binding scaffolds are provided.

Syarifuddin Husain, Ruzianisra Mohamed, Khairul Bariyyah Abd. Halim et al. · 0 citations
Open access Aug 2026

Computational Investigation of HDLP Inhibitors toward Anticancer Drug Design: Molecular Dynamics-Based Binding Energy Evaluation and Binding Pocket Characterization

Findings identify SAHA, CHR3996, ACY1215, HAD5, and HAD3 as promising HDAC inhibitor candidates for further lead optimization, experimental validation, and preclinical anticancer drug development.

Parthiban Gunasingham, Dushanan Ramachandran, D. Dissanayake et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.